These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 11060468)

  • 1. New perspectives in gastric acid suppression: genetic polymorphisms predict the efficacy of proton pump inhibitors.
    Egan LJ; Murray JA
    Dig Dis; 2000; 18(2):58-63. PubMed ID: 11060468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors.
    Thjodleifsson B
    Drugs Aging; 2002; 19(12):911-27. PubMed ID: 12495367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
    Robinson M
    Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.
    Stedman CA; Barclay ML
    Aliment Pharmacol Ther; 2000 Aug; 14(8):963-78. PubMed ID: 10930890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.
    Robinson M; Horn J
    Drugs; 2003; 63(24):2739-54. PubMed ID: 14664653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
    Horn J
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton pump inhibitors--differences emerge in hepatic metabolism.
    McColl KE; Kennerley P
    Dig Liver Dis; 2002 Jul; 34(7):461-7. PubMed ID: 12236477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication.
    Ozdil B; Akkiz H; Bayram S; Bekar A; Akgöllü E; Sandikçi M
    Turk J Gastroenterol; 2010 Mar; 21(1):23-8. PubMed ID: 20533108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.
    Sim SC; Risinger C; Dahl ML; Aklillu E; Christensen M; Bertilsson L; Ingelman-Sundberg M
    Clin Pharmacol Ther; 2006 Jan; 79(1):103-13. PubMed ID: 16413245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic drug interaction profiles of proton pump inhibitors.
    Blume H; Donath F; Warnke A; Schug BS
    Drug Saf; 2006; 29(9):769-84. PubMed ID: 16944963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
    Andersson T
    Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The gastric H,K ATPase as a drug target: past, present, and future.
    Sachs G; Shin JM; Vagin O; Lambrecht N; Yakubov I; Munson K
    J Clin Gastroenterol; 2007 Jul; 41 Suppl 2(Suppl 2):S226-42. PubMed ID: 17575528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion.
    Metz DC
    Digestion; 2000; 62(2-3):73-81. PubMed ID: 11025353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revealing the Mechanistic Pathway of Acid Activation of Proton Pump Inhibitors To Inhibit the Gastric Proton Pump: A DFT Study.
    Jana K; Bandyopadhyay T; Ganguly B
    J Phys Chem B; 2016 Dec; 120(51):13031-13038. PubMed ID: 27992223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitors: new drugs and indications.
    Mears JM; Kaplan B
    Am Fam Physician; 1996 Jan; 53(1):285-92. PubMed ID: 8546054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status.
    Sugimoto M; Furuta T; Shirai N; Ikuma M; Hishida A; Ishizaki T
    Clin Pharmacol Ther; 2006 Nov; 80(5):539-48. PubMed ID: 17112810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: A randomized prospective study.
    Chwiesko A; Charkiewicz R; Niklinski J; Luczaj W; Skrzydlewska E; Milewski R; Baniukiewicz A; Wroblewski E; Rosolowski M; Dabrowski A
    J Dig Dis; 2016 Sep; 17(9):588-599. PubMed ID: 27518195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
    Gawrońska-Szklarz B; Wrześniewska J; Starzyńska T; Pawlik A; Safranow K; Ferenc K; Droździk M
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):375-9. PubMed ID: 15976989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.
    Sharara AI
    Expert Rev Anti Infect Ther; 2005 Dec; 3(6):863-70. PubMed ID: 16307499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
    Furuta T; Takashima M; Shirai N; Xiao F; Hanai H; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2000 Jun; 67(6):684-9. PubMed ID: 10872651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.